Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1491223 | 0.99 | HSP90AA1 (0.57) | HSP90AA1TKT | |
| SCHEMBL13741267 | 0.99 | HSP90AA1 (0.59) | HSP90AA1TKT | |
| Thiamine Ion SCHEMBL22129283 | 0.84 | HSP90AA1 (0.59) | HSP90AA1TKT | |
| Hydrochloric Acid SCHEMBL1491172 | 0.81 | LMNA (0.67) | HSP90AA1TKT | |
| Hydrochloric Acid SCHEMBL15065461 | 0.76 | TKT (0.55) | HSP90AA1TKT | |
| SCHEMBL29761314 | 0.76 | TKT (0.46) | HSP90AA1TKT | |
| Hydrochloric Acid SCHEMBL244784 | 0.76 | HSP90AA1 (0.74) | HSP90AA1TKT | |
| Hydrochloric Acid SCHEMBL1628632 | 0.75 | HSP90AA1 (0.72) | HSP90AA1TKT | |
| Thiamine Ion SCHEMBL10074 | 0.75 | HSP90AA1 (0.98) | HSP90AA1TKT | |
| Hydrochloric Acid SCHEMBL1491222 | 0.75 | HSP90AA1 (0.72) | HSP90AA1TKT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 407 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034158-A1 | METHODS OF TREATING CANCER OF THE CENTRAL NERVOUS SYSTEM COMPRISING 5-ETHYNYL-2'-DEOXYURIDINE | UNIV NORTH CAROLINA CHAPEL HILL (US) | 2026-02-05 | — | — | US | claimed |
| US-20250241869-A1 | COMPOSITIONS AND METHODS COMPRISING DEOXY-PENTITOLS | THE CHARLOTTE MECKLENBURG HOSPITAL AUTHORITY D/B/A ATRIUM HEALTH (US) | 2025-07-31 | — | — | US | claimed |
| WO-2025119420-A1 | COMBINATION THERAPY CONSISTING OF BENFO-OXYTHIAMINE AND/OR OXYTHIAMINE AND RADIONUCLIDE THERAPY | TAVARGENIX GmbH (DE) | 2025-06-12 | — | — | WO | claimed |
| US-12257214-B2 | Compositions and methods comprising deoxy-pentitols | THE CHARLOTTE MECKLENBURG HOSPITAL AUTHORITY (US) | 2025-03-25 | — | — | US | claimed |
| US-20250057843-A1 | USE OF CO-ENZYME ANTAGONISTS TO SLOW METABOLISM | TAVARGENIX GmbH (DE) | 2025-02-20 | — | — | US | claimed |
| WO-2025024123-A1 | NOVEL CITICOLINE DERIVATIVES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-30 | — | — | WO | claimed |
| WO-2025019301-A1 | INHIBITION OF NSUN2 FOR THE TREATMENT OF CANCER | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2025-01-23 | — | — | WO | claimed |
| US-12168010-B2 | Use of co-enzyme antagonists to slow metabolism | TAVARGENIX GmbH (DE) | 2024-12-17 | — | — | US | claimed |
| US-20240374623-A1 | TKTL1 INHIBITORS FOR ANTIVIRAL THERAPY | TAVARGENIX GmbH (DE) | 2024-11-14 | — | — | US | claimed |
| WO-2024182223-A2 | SYNTHESIS AND USE OF SULFONAMIDE ANALOGS OF MEMANTINE AND AMANTADINE | THE UNIVERSITY OF TULSA (US) | 2024-09-06 | — | — | WO | claimed |
| CN-101142486-A | Method for examining and controlling mammalian lactic acid fermentation process/aerobic glucose fermentation metabolic pathway in mammalian organism | JOHANNES COY (DE) | 2008-03-12 | — | — | CN | claimed |
| EP-1856537-A1 | METHOD FOR CHECKING AND CONTROLLING THE MAMMALIAN LACTIC ACID FERMENTATION PROCESS/AEROBIC GLUCOSE FERMENTATION METABOLIC PATHWAY IN MAMMALIAN ORGANISM | Coy, Johannes, Dr. (DE) | 2007-11-21 | — | — | EP | claimed |
| WO-2007025238-A2 | USE OF FRUCTOSE-BASED THERAPIES FOR THE TREATMENT OF CANCER | CEDARS-SINAI MEDICAL CENTER (US) | 2007-03-01 | — | — | WO | claimed |
| WO-2006094716-A1 | METHOD FOR CKECKING AND CONTROLLING THE MAMMALIAN LACTIC ACID FERMENTATION PROCESS/AEROBIC GLUCOSE FERMENTATION METABOLIC PATHWAY IN MAMMALIAN ORGANISM | COY JOHANNES (DE) | 2006-09-14 | — | — | WO | claimed |
| EP-1701165-A1 | Therapeutic and diagnostic uses of TKTL1 and inhibitors and activators thereof | Coy, Johannes, Dr. (DE) | 2006-09-13 | — | — | EP | claimed |
| US-20060002922-A1 | Method for preventing or treating obesity by modulating the activities of the pentose phosphate patway | MINKON BIOTECHNOLOGY, INC. (US) | 2006-01-05 | — | — | US | claimed |
| US-20050159387-A1 | In-vivo energy depleting strategies for killing drug-resistant cancer cells | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2005-07-21 | — | — | US | claimed |
| WO-2003105862-A1 | IN-VIVO ENERGY DEPLETING STRATEGIES FOR KILLING DRUG-RESISTANT CANCER CELLS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2003-12-24 | — | — | WO | claimed |
| US-20030139331-A1 | Treatment of cancer by reduction of intracellular energy and pyrimidines | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2003-07-24 | — | — | US | claimed |
| EP-1092766-A1 | MICROORGANISM BELONGING TO THE GENUS CITROBACTER AND PROCESS FOR PRODUCING SHIKIMIC ACID | TORAY INDUSTRIES, INC. (JP) | 2001-04-18 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060002922-A1 | Method for preventing or treating obesity by modulating the activities of the pentose phosphate patway | PNKP, PNP, TKT | HSP90AA1 3095/4885TKT 3/4885 |
| US-20260034158-A1 | METHODS OF TREATING CANCER OF THE CENTRAL NERVOUS SYSTEM COMPRISING 5-ETHYNYL-2'-DEOXYURIDINE | NSUN2, MKI67, DUT | HSP90AA1 3822/4885TKT 2275/4885 |
| US-20250057843-A1 | USE OF CO-ENZYME ANTAGONISTS TO SLOW METABOLISM | PLPBP, PC, SLC19A2 | HSP90AA1 2696/4885TKT 4/4885 |
| US-12168010-B2 | Use of co-enzyme antagonists to slow metabolism | PLPBP, PC, SLC19A2 | HSP90AA1 2696/4885TKT 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.